MET and neoplasm: Hence, NSCLC cells with de novo deregulated MET signaling may already be present at baseline; however, their clinical significance in intrinsic resistance seems heterogeneous, possibly because of the polyclonality of resistance mechanisms and different levels of MET signaling deregulation or tumor cell addiction to this signaling.